ASHAshland Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range and rich vs its sector.
Priced for ~0% a year FCF growth. Little growth is priced in even as revenue fell 7% a year over three years, potential value, or a value trap.
Expensive vs its own history: P/E 69.5 vs a 24.6 median over 23 quarters (+183% vs median).
Sector median 17.6× across 53 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ASH's price assumes
Ashland Inc. trades at 69.5× earnings against 31.1× for the median Specialty Chemicals name, more expensive than its own group.
Trailing P/E · Specialty Chemicals median 31.1 · 2.24× the median: the market pays up for this one
- Price / sales
- 1.81
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 7.5%
Free cash flow yield · Specialty Chemicals median 4.8%
- Growth the price implies
- +0.30%
Growth the price implies · The price pays for +0.30% free cash flow growth a year for a decade; the business has delivered +8.6% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.79
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 31.2
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.32
- Basic Materials median P/E202 names
- 20.6
- Specialty Chemicals median P/E43 names
- 31.1
- Free cash flow, trailing twelve months
- $250M
- Market capitalisation45.8 million shares, counted Jun 30, 2026
- $3.34B
- 3-year revenue growth
- −7.2%
- 3-year free cash flow growth
- +8.6%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 69.5× today against a 24.6× median |
| 52-week range | $46.81 – $76.45 |
| Today | $73.01 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Specialty Chemicals
Ranks #21 of 33 by RyuScore